Key result
Anti-EGFR agents increased the risk of all-grade venous thromboembolic events in NSCLC patients, but not arterial thromboembolic events.
Why the study?
Do anti-EGFR agents increase the risk of arterial and venous thromboembolic events in patients with non-small-cell lung cancer?
Meta-Analysis (n=8,410)
Do anti-EGFR agents increase the risk of arterial and venous thromboembolic events in patients with non-small-cell lung cancer?
The use of anti-EGFR agents in non-small-cell lung cancer is associated with a significantly increased risk of venous thromboembolic events, highlighting the need for vigilance in this patient population.
Answers are grounded in this paper and cite their sources.
Heightens thromboembolic monitoring in NSCLC on anti-EGFR agents; extends RCT safety data for targeted therapies.
BACKGROUND: To determine the risk of arterial and venous thromboembolic events (ATEs and VETs) associated with anti-epidermal growth factor receptor (EGFR) agents in non-small-cell lung cancer (NSCLC) patients. METHODS: Prospective randomized trials evaluating therapy with or without anti-EGFR agents in NSCLC patients. Data on VTEs and ATEs were extracted. RESULTS: A total of 8,410 patients from 12 trials were included for analysis. Anti-EGFR agents significantly increased the risk of all-grade and high-grade VTEs (Peto OR 1.50, 95%CI 1.16-1.95, P = 0.002; Peto OR 1.73, 95%CI: 1.32-2.26, p < 0.001, respectively), but not for all-grade and high-grade ATEs. CONCLUSION: The use of anti-EGFR agents significantly increased the risk of all-grade and high-grade VTEs but not for ATEs in NSCLC patients.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2016) conducted a meta-analysis in non-small-cell lung cancer (NSCLC) (n=8,410). anti-EGFR agents vs. therapy without anti-EGFR agents was evaluated on all-grade venous thromboembolic events (VTEs) (Peto OR 1.50, 95% CI 1.16-1.95, p=0.002). Anti-EGFR agents increased the risk of all-grade venous thromboembolic events in NSCLC patients, but not arterial thromboembolic events.
Synapse has enriched 10 related papers. Consider them for comparative context: